As advised via PHARMAC tender of 30 April 2018 there is to be a change in the listing and future sole supply.

New listing from 1 November 2018

Dortimopt Eye Drops 2% with timolol 0.5% 5 ml OP                            Pharmacode 2398354         Schedule price $2.87

Incumbent brand

Dortim-Actavis Eye Drops 2% with timolol 0.5% 5 ml OP                     Pharmacode 2480670            Schedule price $3.45   (price decrease to $2.50 ex manufacturer (Teva) and available from your wholesaler from 12 October 2018 thanks to price support provided by Teva)

Reference pricing will apply to the incumbent from 1 January 2019.

HML (Hospital Supply Status) commences 1 January 2019.                                CSS (Community Supply Status) commences 1 April 2019.

As of the date of this notification ProPharma / PWR cannot accept Dortim-Actavis for credit under any circumstances.

We strongly recommend you continue to purchase the incumbent (to improve your bottom line) and we will change automatically as existing stocks are depleted.

Benefit of staying with incumbent – With a variable or reducing margin every cent counts.

From 12 Ocotber 2018 to 30 November 2018:-

$3.45 x 3% = $0.1035 plus $0.253 per pack fee plus $0.97 buying advantage  = $1.3065 compared to $2.87 x 3% = $0.0861 plus $0.253 per pack fee = $0.3391

From 1 December 2018 to 31 March 2019:-

$2.87 x 3% = $0.0861 plus $0.253per pack fee plus $0.37 buying advantage  = $0.7091 compared to $2.87 x 3% = $0.0861 plus $0.253 per pack fee = $0.3391

With the support provided by Teva and passed on in full by ProPharma/PWR you have no need to change until late March 2019 or when stocks are depleted, whichever comes first.

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author